Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

A. Brodsky, Robert; S. Young, Neal; Antonioli, Elisabetta; M. Risitano, Antonio; Schrezenmeier, Hubert; Schubert, Jörg; Gayà, Anna; Coyle, Luke; de Castro Lozano, Carlos; Fu, Chieh‐Lin; P. Maciejewski, Jaroslaw; Bessler, Monica; Kroon, Henk-André; P. Rother, Russell; Hillmen, Peter

doi:10.1182/blood-2007-06-094136

Public

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Published in Blood • Nov 30, 2007

Authors:

Robert A. Brodsky

Neal S. Young

Elisabetta Antonioli

Abstract

The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations with results from an open-label, non-placebo-controlled, 52-week, phase 3 clinical safety and efficacy s...

Subject

Eculizumab

Paroxysmal nocturnal hemoglobinuria

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!